News & Updates
Showing Endocrinology articles
Showing
Show Multimedia Only

Triple win for fixed-dose combo in T2D
08 Jul 2026
byElvira Manzano
A fixed-dose combination of the novel amylin receptor agonist cagrilintide and the approved GLP-1 receptor agonist semaglutide (CagriSema) yields better HbA1c control and weight loss in patients with type 2 diabetes (T2D) than either therapy alone or placebo in three phase III trials from the global REIMAGINE programme presented at ADA 2026. The benefits also extend to patients on insulin therapy.








